Eastern Hepatobilliary Surgical Hospital
Although resection of hepatocellular carcinoma is potentially curative, local recurrence is
common with the recurrence rate higher than 50% during 5 years. So to reduce the recurrence
rate of HCC, some interventions had been tried in clinic, including transarterial
chemoembolization (TACE), immunotherapy, and interferon treatment etc. But few of these
adjuvant therapies had been proved effective and their long term efficacy and clinical
application remained further explored.
TACE had been prove to be effective in patients with advanced stage of HCC in randomized
controlled trials and meta-analysis, but the role of adjuvant TACE after liver resection is
controversial. The results getting from different randomized control trials varied
significantly because of the bias of patient selection, different study design，the small
size of sample, different drug used in chemotherapy and lack of proper stratification…,so a
big sample size, well patients selected and well designed randomized controlled trial is
needed to further confirm the role of the postoperative TACE.
Patients with HCC who received curative liver resection (R0) were randomly assigned 1:1 by
the doctors to receive no adjuvant TACE(control group) or TACE(treatment group). All
patients in the treatment group received adjuvant TACE 45 days after liver resection. The
outcomes of patients were evaluated during the 3-years follow up.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Shen feng, MD
Eastern hepatobilliary surgery hospital
China: Ministry of Health